(b).
| SAT II follow-up scores | BPI-DN item 9F | Overall F value2 (p-value) | Pairwise comparisons3 | ||
|---|---|---|---|---|---|
| 0–3 N, mean (SD)1 |
4–6 N, mean (SD)1 |
7–10 N, mean (SD)1 |
|||
| Week 8 | |||||
| Pain improvement | 186, 1.73 (1.41) | 86, 0.95 (1.14) | 63, 0.41 (0.66) | 30.80∗∗∗ | 1∗∗∗, 2∗∗∗, 3∗ |
| Impact summary | 184, 1.49 (1.34) | 85, 0.81 (0.93) | 63, 0.46 (0.71) | 23.21∗∗∗ | 1∗∗∗, 2∗∗∗ |
| Treatment continuation | 182, 2.97 (1.17) | 85, 2.45 (1.27) | 63, 2.46 (1.24) | 7.55∗∗ | 1∗∗, 2∗ |
| Treatment comparison | 182, 2.97 (0.92) | 85, 2.49 (0.88) | 63, 2.14 (0.69) | 23.91∗∗∗ | 1∗∗∗, 2∗∗∗ |
| Week 12 | |||||
| Pain improvement | 176, 1.66 (1.49) | 79, 0.61 (1.01) | 62, 0.45 (0.74) | 31.00∗∗∗ | 1∗∗∗, 2∗∗∗ |
| Impact summary | 175, 1.37 (1.34) | 77, 0.72 (1.01) | 62, 0.58 (0.84) | 14.55∗∗∗ | 1∗∗∗, 2∗∗∗ |
| Treatment continuation | 175, 2.85 (1.28) | 77, 2.34 (1.39) | 62, 2.27 (1.51) | 6.23∗∗ | 1∗, 2∗ |
| Treatment comparison | 172, 2.84 (0.95) | 77, 2.38 (0.93) | 62, 2.08 (0.95) | 17.20∗∗∗ | 1∗∗, 2∗∗∗ |
1SAT II mean scores and SD for patients with a BPI-DN item 9F score within the specified range.
2An analysis of variance (ANOVA).
3Pairwise comparisons between means were performed using Scheffé's test adjusting for multiple comparisons; 1 = 0–3 versus 4–6; 2 = 0–3 versus 7–10; 3 = 4–6 versus 7–10; ∗p < 0.05, ∗∗p < 0.001, and ∗∗∗p < 0.0001.